Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Berruti, A ^a   Baudin, E ^b   Gelderblom, H ^c   Haak, H R ^d   Porpiglia, F ^a   Fassnacht, M ^e   Pentheroudakis, G ^f  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXAZOSIN; DOXORUBICIN; ESMOLOL; ETOPOSIDE; GLYCERYL TRINITRATE; IODINE 131; MAGNESIUM SULFATE; MITOTANE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PHENTOLAMINE; PROTEIN P53; SOMATOMEDIN B; STREPTOZOCIN; VINCRISTINE;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INSULIN LIKE GROWTH FACTOR II GENE; METASTASIS; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SUCCINATE DEHYDROGENASE B GENE; SUCCINATE DEHYDROGENASE C GENE; TACHYCARDIA; TP53 GENE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 84866628998     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds231     Document Type: Article

References (31)

1. Fassnacht M, Libé R, Kroiss M et al. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7: 323-335.
2. Pacak K, Eisenhofer G, Ahlman H et al. International symposium on pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the first international symposium. October 2005. Nat Clin Pract Endocrinol Me tab 2007; 3: 92-102.
3. Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab 2009; 23: 261-271.
4. Esenhofer G, Lenders JW, Siegert G et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012; 48: 1739-1749.
5. Arlt W, Biehl M, Taylor AE et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96: 3775-3784.
6. Timmers HJ, Kozupa A, Chen CC et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007; 25: 2262-2269.
7. Sbiera S, Schmull S, Assie G et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010; 95: E161-E171.
8. Weiss LM, Medeiros LJ, Vickery AL, Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13: 202-206.
9. Fassnacht M, Johanssen S, Quinkler M et al. German adrenocortical carcinoma registry group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classi?cation. Cancer 2009; 115: 243-250.
10. Baudin E, Leboulleux S, Al Ghuzlan A et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 2011; 6: 363-371.
11. de Reyniès A, Assié G, Rickman DS et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identi?es molecular predictors of malignancy and survival. J Clin Oncol 2009; 27: 1108-1115
12. Ayala-Ramirez M, Feng L, Johnson MM et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011; 96: 717-725.
13. Amar L, Baudin E, Burnichon N et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007; 92: 3822-3828.
14. Lombardi CP, Raffaelli M, Boniardi M et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg 2012; 397: 201-207.
15. Porpiglia F, Fiori C, Daffara F et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57: 873-878.
16. Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25: 891-897.
17. Reibetanz J, Jurowich C, Erdogan I et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255: 363-369.
18. Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12: 667-680.
19. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069-4079.
20. Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90: 2110-2116.
21. Polat B, Fassnacht M, Pfreundner L et al. Radiotherapy in adrenocortical carcinoma. Cancer 2009; 115: 2816-2823.
22. Terzolo M, Angeli A, Fassnacht M et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380.
23. Berruti A, Fassnacht M, Baudin E et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 2010; 28: e401-e402.
24. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951.
25. Hermsen IG, Fassnacht M, Terzolo M et al. Plasma concentrations of o,p'DDD, o, p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96: 1844-1851.
26. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197.
27. Bukowski RM, Wolfe M, Levine HS et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993; 11: 161-165.
28. van Erp NP, Guchelaar HJ, Ploeger BA et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164: 621-626.
29. Ayala-Ramirez M, Feng L, Habra MA et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic 675 extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012; 118: 2804-2812.
30. Kroiss M, Quinkler M, Lutz WK et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. 665 Clin Endocrinol (Oxf) 2011; 75(5): 585-591.
31. Gonias S, Goldsby R, Matthay KK et al. Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009; 27: 4162-4168.